JUST WATCHED

    Novartis, GlaxoSmithKline ink $20B deal

MUST WATCH

Novartis, GlaxoSmithKline ink $20B deal

Jim Boulden speaks to the CEO's of GSK and Novartis about why they've agreed to swap assets and combine business units.

Novartis, GlaxoSmithKline ink $20B deal

Jim Boulden speaks to the CEO's of GSK and Novartis about why they've agreed to swap assets and combine business units.